Hepatitis Forums

Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on May 04, 2017, 10:07:01 am

Title: Eight Weeks of AbbVie’s G/P Cures Almost All Those With Genotype 3 of Hep C
Post by: Hep Editors on May 04, 2017, 10:07:01 am

An eight-week regimen of AbbVie’s investigational glecaprevir/pibrentasvir, known as G/P, cured a high rate of those with genotype 3 of hepatitis C virus (HCV) who had not been treated for the virus before and did not have cirrhosis according to a recent study. Additionally, the study found that 12 weeks of G/P treated this demographic as well as 12 weeks of Sovaldi (sofosbuvir) plus Daklinza (daclatasvir).

AbbVie applied for FDA approval of G/P in February. A decision is expected in late June.

For more...
https://www.hepmag.com/article/eight-weeks-abbvies-gp-cures-almost-genotype-3-hep-c